UK Startup Funding Report: £439.0m raised across Biotech, Healthtech and Fintech (2–6 Nov 2026).
It's Friday, 6 November, and this is your UK Startup Funding Report.
UK startups raised a total of £439.0M this week, led by large biotech and fintech rounds alongside healthtech deals pushing products toward clinical and commercial scale. Rounds ranged from strategic minority investments to series B and series A financings that will fund trials, international expansion and heavy capital investment.
AI: hardware and specialised applications both attract capital
Startups building core AI infrastructure and vertical AI products took centre stage this week as investors split their attention between compute-backed capacity and specialised, evidence-led applications. The distinction matters: scaling large models depends on access to GPU capacity, while many enterprises need domain-specific tools that turn frontline insight into measurable use cases.
The deal flow reflects that split. NexGen Cloud secured a £79.41 million senior secured facility led by USD.AI to finance deployment of 216 NVIDIA HGX B300 servers, an explicitly hardware-backed debt structure tied to contracted cashflows. On the equity side, Ares Intelligence raised £2.5 million in a seed round to expand an employee-interviewing platform that generates AI-led roadmaps; Mindmax took £3 million in pre-seed to build an AI conversational tutor for professional exams; and Potential Sciences emerged from stealth with undisclosed capital and compute commitments to develop atomistic foundation models for physics-driven drug discovery.
Taken together, the rounds underline a regional pattern: funders are prepared to support capital-intensive infrastructure with debt while using equity to back specialised software that can demonstrate measurable impact. Investors are therefore populating both ends of the stack, matching financing type to a company’s capital profile.
This week's AI deals:
NexGen Cloud secured a £79.4M senior secured facility led by USD.AI to finance deployment of 216 NVIDIA HGX B300 servers and expand GPU-backed financing across Europe. The debt package is structured around hardware and contracted cashflows to accelerate capacity for large-scale AI workloads without diluting equity.
Ares Intelligence raised £2.5M in seed funding led by Creandum and Lakestar to expand its employee-interviewing platform that generates evidence‑led AI roadmaps. The product captures frontline insight at scale and turns it into prioritised use cases for automation and AI deployment.
Mindmax raised £3M in a pre‑seed round to build an AI-powered conversational tutor for professionals preparing for exams and reskilling. The funds will develop personalised learning flows and scale product features designed to improve retention and measurable outcomes.
Potential Sciences emerged from stealth with significant capital and compute commitments to build a large quantum‑chemistry dataset and atomistic foundation models, though no headline amount was disclosed. The seed will scale high‑fidelity QM data generation and train models intended to accelerate physics‑driven drug discovery.
Fintech: infrastructure and regulated AI tooling draw capital
This week’s fintech activity shows investors backing both market infrastructure that supports cross-border execution and AI-enabled tooling tailored to regulated workflows. Durable execution systems are needed to bridge traditional and on-chain markets, while regulated finance demands verifiable provenance and audit trails.
Notable rounds illustrate that balance. Hoxton Wealth accepted a strategic minority investment of £100.7 million from Aspirity Partners I to support international expansion and product development while leaving founders as majority shareholders. LO:TECH raised £8.96 million in a Series A led by MMC to expand into New York and Singapore and to scale execution services across traditional and on-chain venues. Tallia closed a £3 million seed led by Outward VC to scale an AI platform for tax advisers that integrates provenance and office tools, and Crediflow AI secured £1.5 million to automate commercial loan preparation and financial spreading.
Investors are therefore balancing bets on cross-border execution infrastructure and domain-specific AI that reduces friction in regulated processes—an approach likely to support further international expansion and integration with incumbent systems.
This week's Fintech deals:
Hoxton Wealth took its first external capital with a strategic minority investment from Aspirity Partners I worth £100.7M. The founders say the funds will back international expansion, senior hires and continued development of its adviser-facing technology while leaving the founder as majority shareholder.
LO:TECH raised £9M in a Series A led by MMC to fund expansion into New York and Singapore and to scale execution services for institutional trading across traditional and on‑chain venues. The round backs the firm's plan to provide always‑on trading infrastructure for tokenised and traditional assets.
Tallia closed a £3M seed round led by Outward VC to scale an AI platform that helps tax advisers research, draft and audit advice with verifiable provenance. The product aims to cut research time, produce audit trails and integrate with office tools used by accounting firms.
Crediflow AI secured £1.5M to develop automation that speeds up commercial loan preparation and financial spreading for banks and specialist lenders. The platform aims to cut document aggregation and credit memo drafting from days to minutes, widening lenders' underwriting capacity for SMEs.
Biotech & Healthtech: capital targets clinical and regulatory inflection points
Funding this week concentrated on clinical-stage therapeutics alongside diagnostics and medtech, with larger Series A/B rounds aimed at clinical milestones and smaller financings focused on regulatory or manufacturing steps. That pattern reflects the capital intensity of drug development, where clear trial or approval pathways tend to determine round size.
Major rounds included T-Therapeutics’ £100 million Series B co-led by Advent Life Sciences and the British Business Bank to advance two T cell receptor programmes into clinical trials, and Alethio Therapeutics’ oversubscribed £67 million Series A—backed by Sofinnova, RA Capital and Oxford Science Enterprises—to push a lead antibody towards IND-enabling studies. OSSTEC secured £5.97 million to fund U.S. first-in-human surgical cases of its 3D-printed cementless partial knee implant and related FDA activities, while Bioliberty raised £7.7 million led by the Scottish National Investment Bank to scale manufacturing and U.S. commercial expansion of a soft-robotic rehabilitation glove.
The cluster of clinical and regulatory-focused rounds underlines investor preference for companies with defined pathways to trials or approvals. Public and quasi-public backers remain visible players in de-risking capital for scale-up.
This week's Biotech & Healthtech deals:
T-Therapeutics raised £100M in a series B co-led by Advent Life Sciences and the British Business Bank to take two lead T cell receptor programmes into clinical trials. The capital will fund preclinical completion and first-in-human studies aimed at oncology and immunology indications.
Oxford spin‑out Alethio closed an oversubscribed £67M series A to advance its lead antibody ATX-011 toward IND‑enabling studies and early clinical trials for myeloproliferative neoplasms. Investors cited differentiated human biology and plans to progress a clear translational path into the clinic.
OSSTEC closed £6M to fund U.S. first‑in‑human surgical cases of ASCENT, its 3D‑printed cementless partial knee implant, and to support FDA clearance activity and surgeon training. The financing will help the company move from regulatory preparation into clinical use and expand U.S. operations.
Bioliberty raised £7.7M in a round led by the Scottish National Investment Bank to scale manufacturing and U.S. commercial expansion of its Lifeglov soft‑robotic rehabilitation glove. The capital will support product development, local manufacturing and broader clinical deployments.
Greentech & Industrial Deeptech: pilots and industrial partnerships secure funding
Investors directed capital into scalable industrial climate technologies that pair chemistry and manufacturing with route-to-market partners. Demonstrator facilities and industrial validation are increasingly prerequisites, because decarbonisation and safer chemical processes require proof of economics at scale.
The week’s rounds included FluoRok’s oversubscribed £22.3 million Series A to scale an HF-free manufacturing platform for fluorochemicals and fund demonstrator facilities; Viridi’s £2.2 million to scale pilot production of CO2-to-chemicals technology and commercialise a CO2-based surfactant; Luthmore’s £4.5 million to commercialise a battery-enabled, zero-emissions boiler and support UK rollouts; and Rookwood Operations’ £800,000 to commercialise a nature-based process that removes phosphate from waterways and converts it into reusable fertiliser.
Together, these deals point to a regional preference for funding capital‑intensive pilots that have clear industrial partners or an obvious route to market, rather than speculative lab plays.
This week's Greentech & Industrial Deeptech deals:
FluoRok raised £22.3M in an oversubscribed series A to scale an HF‑free manufacturing platform for fluorochemicals used in pharmaceuticals, agrochemicals and batteries. The funds will build demonstrator facilities, validate industrial-scale production and expand the team to commercialise the safer production route.
Viridi raised £2.2M to scale pilot production of CO2‑to‑chemicals technology and commercialise its CO2‑based surfactant Vireya. The funds will support pilot scale‑up, hiring and initial market entry in Asia and the US with strategic industrial partners.
Luthmore raised £4.5M to commercialise its battery‑enabled, zero‑emissions Luthmore One boiler and to fund sales and installer training as it rolls out UK installations. The raise supports early deployments and the company’s effort to offer a lower‑carbon alternative to gas combi boilers.
Rookwood raised £800k to commercialise a nature‑based process that removes phosphate from waterways and converts it into reusable fertiliser. The round will fund deployments with water companies and scale production while the business leverages Innovate UK awards and regional investment.
Proptech, consumer and events: consolidation and product-led growth
This week’s sector-specific winners include proptech roll-up plays, consumer growth rounds and a rare external investment into a long-standing events business. The mix shows investors back both acquisition-led consolidation and product-led scale outside deeptech verticals.
Supa raised £21 million in a seed round to accelerate acquisitions of local managing agents and develop an AI-led operating system for block property management. Sporta closed a £5 million growth round to support expansion, though operational detail in its announcement was limited. Skiddle accepted its first external investment in 25 years in a growth deal led by Soho Square Capital; the round size was undisclosed and the capital will fund technology upgrades and planned European expansion while preserving founder control.
Watch how quickly Supa can execute bolt-on deals and whether Skiddle uses its new backing to modernise systems ahead of cross‑border moves; the outcomes will signal how attractive consolidation strategies remain in these sub-sectors.
This week's Other (Proptech, Edtech, Ecommerce & Marketplaces) deals:
Supa raised £21M in a seed round to accelerate acquisitions of local managing agents and develop its AI-led operating system for block property management. The company will use the capital to scale M&A-driven roll‑outs and improve resident-facing operations through automation.
Sporta closed a £5M growth round to support the consumer business’s next phase of growth, though operational details were sparse in the announcement. The funding is intended to accelerate expansion while the company clarifies product and go‑to‑market plans.
Skiddle accepted its first external investment in 25 years in a growth deal led by Soho Square Capital; the company did not disclose the round size. The capital is intended to accelerate expansion into lifestyle events, upgrade technology and support planned European growth while preserving founder control.
🎧 That's this week's Startupmag Weekly Briefing.
See you next Friday for another look at the UK startup scene.